查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423555

到 2030 年流感诊断测试市场预测：按测试类型、最终用户和地区进行的全球分析

Influenza Diagnostic Tests Market Forecasts to 2030 - Global Analysis By Test Type, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球流感诊断检测市场规模将达到 11 亿美元，预计 2030 年将达到 17 亿美元，预测期内复合年增长率为 5.6%。

流感诊断测试是一种医疗程序，旨在识别出现呼吸道症状的个体是否存在流感病毒。恒温环型核酸扩增(LAMP) 和基于核酸序列的扩增 (NASBA) 等新技术提供了更快、更方便的替代方案。快速且准确的诊断对于及时治疗和有效的公共卫生措施、放大和检测病毒并提供准确的结果至关重要。

美国疾病管制与预防美国估计，2021-2022年季节，美国将出现900万例流感病例、400万例与流感相关的就诊、10万人例与流感相关的住院治疗以及5,000例与流感相关的死亡。到 COVID-19 爆发前的最近几个季度，83% 的死亡病例是老年人。

意识和教育

健康素养计画教育人们识别流感症状，了解疾病的潜在严重性，并了解诊断测试在有效治疗和预防中的作用。公共卫生宣传活动、教育措施和沟通工作有助于意识提升。此外，医疗保健提供者正在提高识别和应对流感病例的能力，推动了该市场的扩张。

高成本

流感诊断测试的高昂成本可能会阻止医疗保健提供者和患者使用该测试，特别是在资源有限的环境和卫生预算有限的地区。这可能导致诊断不足、治疗延迟和疾病管理不善。此外，还可能产生与进行测试相关的额外成本，例如专业费用和检体采集耗材，从而阻碍市场成长。

诊断技术的进步

分子诊断技术，特别是逆转录聚合酶链反应（RT-PCR）的显着进步，提高了流感病毒检测的敏感度和特异性。这些进步能够快速且准确地识别病毒株，帮助医疗保健专业人员及时做出决策并管理患者。此外，免疫测量和核酸扩增技术不断发展，有助于诊断选择的多样化。

缺乏意识

医疗保健提供者可能不熟悉每次测试的好处、局限性和结果的适当解释。这可能导致诊断测试的利用不足或使用不当，从而导致诊断延迟和患者管理不理想。此外，许多人可能没有意识到它的重要性，这透过减少对检测服务的需求并导致错失早期检测和有效疾病管理的机会来阻碍这个市场。

COVID-19 的影响

COVID-19 大流行从多个方面对流感诊断测试市场产生了负面影响。随着世界各地的医疗保健系统优先考虑 COVID-19 诊断，对流感诊断测试的整体需求有所下降。 COVID-19 和流感的症状经常重迭，因此仅根据临床症状很难区分两者。此外，疫情也影响了医疗保健支出的优先顺序，这可能会影响流感诊断技术的投资并阻碍市场扩张。

分子诊断分析领域预计将成为预测期内最大的领域

分子诊断检测领域估计占据最大份额，因为它是利用分子生物学技术检测和识别流感病毒的检测类别。这些测试以其高灵敏度、特异性和区分不同流感亚型的能力而闻名。此外，透过逆转录聚合酶炼式反应（RT-PCR）等重要方法，我们正在为更全面地了解流行的流感病毒的遗传特征做出贡献，从而推动这一领域的成长。

研究机构细分市场预计在预测期内复合年增长率最高

研究机构在预测期内将拥有最高的复合年增长率，因为它们透过开展旨在提高现有检测的敏感性、特异性和效率的研究，在流感诊断领域的发展中发挥关键作用，预计这种情况将会发生。研究机构正在努力开发新的诊断检测方法，包括先进的分子技术、即时检测设备和血清学检测方法。此外，研究实验室在检验新诊断技术并提供关键资料来指南医疗保健专业人员方面发挥关键作用。

比最大的地区

由于越来越多地采用先进的诊断技术，包括提供更高灵敏度和特异性的 PCR 等分子检测技术，亚太地区在预测期内占据了最大的市场占有率。该地区是 BioConcept、Abbott、Quidel Corporation 和 Thermo Fisher Scientific Inc. 等主要市场的所在地。此外，该地区人口密度高、互联性强，强调需要采取有效的流感监测和控制措施，从而推动该地区市场的发展。

复合年增长率最高的地区：

由于其发达的医疗基础设施和对感染疾病的高度认识，预计北美在预测期内将呈现最高的复合年增长率。 RT-PCR 等分子诊断检测方法的采用越来越多，它们在流感检测中具有高灵敏度和准确性。此外，诊断技术的持续创新使我们能够应对新的病毒株和全球健康挑战，并支持该地区的成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球流感诊断测试市场：按测试类型

  • 分子诊断分析
    • 基于简单扩增的测定 (SAMBA)
    • RT-PCR
    • 基于核酸序列的扩增检验 (NASBAT)
    • 基于恒温环型核酸扩增的测定（LAMP）
    • 其他分子诊断测定
  • 传统诊断测试
    • 病毒培养
    • 流感快速诊断检验 (RIDT)
    • 血清学检测
    • 直接萤光抗体测试 (DFAT)
  • 其他测试类型

第六章全球流感诊断测试市场：依最终用户分类

  • 研究
  • 医院
  • 诊断中心
  • 其他最终用户

第七章全球流感诊断测试市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第八章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第九章 公司简介

  • Becton, Dickinson and Company
  • Coris BioConcept
  • Meridian Bioscience Inc.
  • Abbott
  • Sekisui Diagnostics
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • DiaSorin SpA
  • Quidel Corporation
  • Thermo Fischer Scientific Inc.
Product Code: SMRC24789

According to Stratistics MRC, the Global Influenza Diagnostic Tests Market is accounted for $1.1 billion in 2023 and is expected to reach $1.7 billion by 2030 growing at a CAGR of 5.6% during the forecast period. Influenza diagnostic tests are medical procedures designed to identify the presence of influenza viruses in individuals experiencing respiratory symptoms. Emerging technologies, such as loop-mediated isothermal amplification (LAMP) and nucleic acid sequence-based amplification (NASBA), offer faster and simpler alternatives. Rapid and accurate diagnosis is crucial for prompt treatment and effective public health measures that amplify and detect viruses, providing accurate results.

According to estimates by the Centers for Disease Control and Prevention, there were 9 million flu cases, 4 million influenza-related medical appointments, 100,000 flu-related hospitalizations, and 5,000 flu-related fatalities during the 2021-2022 seasons in the U.S. Similar to recent seasons preceding the COVID-19 outbreak, 83% of fatalities were caused by older people.

Market Dynamics:

Driver:

Increased awareness and education

Health literacy programs educate individuals on recognizing influenza symptoms, understanding the potential severity of the disease, and appreciating the role of diagnostic tests in effective treatment and prevention. Public health campaigns, educational initiatives, and communication efforts contribute to raising awareness among healthcare professionals and the general public. Furthermore, healthcare providers are better equipped to recognize and respond to influenza cases, which are boosting this market expansion.

Restraint:

High cost

The high costs associated with influenza diagnostic tests can deter healthcare providers and patients from utilizing them, particularly in resource-limited settings or regions with constrained healthcare budgets. This can result in underdiagnosis, delayed treatment, and compromised disease management. In addition, there may be additional expenses related to test administration, such as professional fees and specimen collection supplies, hampering market growth.

Opportunity:

Advancements in diagnostic technologies

Molecular diagnostic technologies, notably reverse transcription-polymerase chain reaction (RT-PCR), have seen remarkable progress, offering heightened sensitivity and specificity in detecting influenza viruses. These advancements enable rapid and accurate identification of viral strains, aiding healthcare professionals in timely decision-making and patient management. Moreover, immunoassays and nucleic acid amplification techniques continue to evolve, contributing to a diverse array of diagnostic options, thereby driving this market size.

Threat:

Lack of awareness

Healthcare providers may not be familiar with the advantages, limitations, and proper interpretation of the results associated with each test. This can lead to underutilization or inappropriate utilization of diagnostic tests, potentially resulting in delayed diagnosis and suboptimal patient management. Moreover, many individuals may not be aware of its importance, which contributes to a lower demand for testing services, leading to missed opportunities for early detection and effective disease control and impeding this market.

Covid-19 Impact

The COVID-19 pandemic has had a negative impact on the influenza diagnostic test market in several ways. Healthcare systems worldwide have prioritized COVID-19 diagnostics, leading to a decrease in the overall demand for influenza diagnostic tests. The symptoms of COVID-19 and influenza often overlap, making it challenging to differentiate between the two based solely on clinical presentations. Further, the pandemic has also influenced healthcare spending priorities, potentially affecting investments in diagnostic technologies for influenza and hindering the market's expansion.

The molecular diagnostic assay segment is expected to be the largest during the forecast period

The molecular diagnostic assay segment is estimated to hold the largest share due to a category of tests that utilize molecular biology techniques to detect and identify influenza viruses. These tests are known for their high sensitivity, specificity, and capacity to distinguish between different influenza subtypes. Moreover, they contribute to a more comprehensive understanding of the genetic characteristics of circulating influenza viruses using prominent methods like reverse transcription-polymerase chain reaction (RT-PCR), boosting this segment's growth.

The research laboratories segment is expected to have the highest CAGR during the forecast period

The research laboratories segment is anticipated to have highest CAGR during the forecast period, due to they play a pivotal role in advancing the field of influenza diagnostics by conducting studies that aim to enhance the sensitivity, specificity, and efficiency of existing tests. They engage in the development of novel diagnostic assays, such as advanced molecular techniques, point-of-care testing devices, and serological assays. Furthermore, Research laboratories also play a key role in validating new diagnostic technologies providing essential data to guide healthcare practitioners propelling this segment's expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to a growing adoption of advanced diagnostic technologies, including molecular assays like PCR, as they offer higher sensitivity and specificity. This region is home to some of the major key markets, such as BioConcept, Abbott, Quidel Corporation, and Thermo Fisher Scientific Inc. In addition, the region's high population density and interconnectedness emphasize the need for effective influenza surveillance and control measures that drive the market in this region.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to a well-established healthcare infrastructure and a high level of awareness regarding infectious diseases. There is a widespread adoption of molecular diagnostic assays such as RT-PCR, which offer high sensitivity and accuracy in influenza detection. Moreover, continuous innovation in diagnostic technologies, ensuring that they align with emerging viral strains and global health challenges, thereby boosts this region's growth.

Key players in the market

Some of the key players in the Influenza Diagnostic Tests Market include Becton, Dickinson and Company , Coris BioConcept, Meridian Bioscience Inc., Abbott, Sekisui Diagnostics, F. Hoffmann-La Roche Ltd, Hologic Inc., DiaSorin SpA, Quidel Corporation and Thermo Fischer Scientific Inc.

Key Developments:

In September 2023, Navigate BioPharma Services, Inc., announced a strategic collaboration with BD (Becton, Dickinson and Company), to explore opportunities to develop and commercialize flow cytometry-based companion diagnostics and tools for clinical decisions.

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

In July 2023, Thermo Fisher Scientific Inc. announced it has entered into a definitive agreement to acquire CorEvitas, LLC ("CorEvitas"), for approved medical treatments and therapies, from Audax Private Equity ("Audax").

In May 2023, Thermo Fisher, has signed a Memorandum of Understanding ("MOU") with the National Research and Innovation Agency of Indonesia (BRIN, Badan Riset dan Inovasi Nasional) to enable and enhance the country's national research and innovation infrastructure and capability.

Test Types Covered:

  • Molecular Diagnostic Assay
  • Traditional Diagnostic Test
  • Other Test Types

End Users Covered:

  • Research Laboratories
  • Hospitals
  • Diagnostics Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Influenza Diagnostic Tests Market, By Test Type

  • 5.1 Introduction
  • 5.2 Molecular Diagnostic Assay
    • 5.2.1 Simple Amplification-Based Assay (SAMBA)
    • 5.2.2 RT-PCR
    • 5.2.3 Nucleic Acid Sequence-Based Amplification Test (NASBAT)
    • 5.2.4 Loop-Mediated Isothermal Amplification-Based Assay (LAMP)
    • 5.2.5 Other Molecular Diagnostic Assays
  • 5.3 Traditional Diagnostic Test
    • 5.3.1 Viral Culture
    • 5.3.2 Rapid Influenza Diagnostic Test (RIDT)
    • 5.3.3 Serological Assay
    • 5.3.4 Direct Fluorescent Antibody Test (DFAT)
  • 5.4 Other Test Types

6 Global Influenza Diagnostic Tests Market, By End User

  • 6.1 Introduction
  • 6.2 Research Laboratories
  • 6.3 Hospitals
  • 6.4 Diagnostics Centers
  • 6.5 Other End Users

7 Global Influenza Diagnostic Tests Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Becton, Dickinson and Company
  • 9.2 Coris BioConcept
  • 9.3 Meridian Bioscience Inc.
  • 9.4 Abbott
  • 9.5 Sekisui Diagnostics
  • 9.6 F. Hoffmann-La Roche Ltd
  • 9.7 Hologic Inc.
  • 9.8 DiaSorin SpA
  • 9.9 Quidel Corporation
  • 9.10 Thermo Fischer Scientific Inc.

List of Tables

  • Table 1 Global Influenza Diagnostic Tests Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Influenza Diagnostic Tests Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 3 Global Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 4 Global Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2021-2030) ($MN)
  • Table 5 Global Influenza Diagnostic Tests Market Outlook, By RT-PCR (2021-2030) ($MN)
  • Table 6 Global Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 7 Global Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2021-2030) ($MN)
  • Table 8 Global Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2021-2030) ($MN)
  • Table 9 Global Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 10 Global Influenza Diagnostic Tests Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 7 Global Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 8 Global Influenza Diagnostic Tests Market Outlook, By Serological Assay (2021-2030) ($MN)
  • Table 9 Global Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 14 Global Influenza Diagnostic Tests Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 15 Global Influenza Diagnostic Tests Market Outlook, By End User (2021-2030) ($MN)
  • Table 16 Global Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 17 Global Influenza Diagnostic Tests Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 18 Global Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2021-2030) ($MN)
  • Table 19 Global Influenza Diagnostic Tests Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 20 North America Influenza Diagnostic Tests Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Influenza Diagnostic Tests Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 22 North America Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 23 North America Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2021-2030) ($MN)
  • Table 24 North America Influenza Diagnostic Tests Market Outlook, By RT-PCR (2021-2030) ($MN)
  • Table 25 North America Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 26 North America Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2021-2030) ($MN)
  • Table 27 North America Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2021-2030) ($MN)
  • Table 28 North America Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 29 North America Influenza Diagnostic Tests Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 30 North America Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 31 North America Influenza Diagnostic Tests Market Outlook, By Serological Assay (2021-2030) ($MN)
  • Table 32 North America Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 33 North America Influenza Diagnostic Tests Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 34 North America Influenza Diagnostic Tests Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 North America Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 36 North America Influenza Diagnostic Tests Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 37 North America Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2021-2030) ($MN)
  • Table 38 North America Influenza Diagnostic Tests Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 39 Europe Influenza Diagnostic Tests Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Influenza Diagnostic Tests Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 41 Europe Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 42 Europe Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2021-2030) ($MN)
  • Table 43 Europe Influenza Diagnostic Tests Market Outlook, By RT-PCR (2021-2030) ($MN)
  • Table 44 Europe Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 45 Europe Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2021-2030) ($MN)
  • Table 46 Europe Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2021-2030) ($MN)
  • Table 47 Europe Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 48 Europe Influenza Diagnostic Tests Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 49 Europe Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 50 Europe Influenza Diagnostic Tests Market Outlook, By Serological Assay (2021-2030) ($MN)
  • Table 51 Europe Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 52 Europe Influenza Diagnostic Tests Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 53 Europe Influenza Diagnostic Tests Market Outlook, By End User (2021-2030) ($MN)
  • Table 54 Europe Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 55 Europe Influenza Diagnostic Tests Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 56 Europe Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2021-2030) ($MN)
  • Table 57 Europe Influenza Diagnostic Tests Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 58 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 60 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 61 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2021-2030) ($MN)
  • Table 62 Asia Pacific Influenza Diagnostic Tests Market Outlook, By RT-PCR (2021-2030) ($MN)
  • Table 63 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 64 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2021-2030) ($MN)
  • Table 65 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2021-2030) ($MN)
  • Table 66 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 67 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 68 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 69 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Serological Assay (2021-2030) ($MN)
  • Table 70 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 71 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 72 Asia Pacific Influenza Diagnostic Tests Market Outlook, By End User (2021-2030) ($MN)
  • Table 73 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 74 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 75 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2021-2030) ($MN)
  • Table 76 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 77 South America Influenza Diagnostic Tests Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Influenza Diagnostic Tests Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 79 South America Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 80 South America Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2021-2030) ($MN)
  • Table 81 South America Influenza Diagnostic Tests Market Outlook, By RT-PCR (2021-2030) ($MN)
  • Table 82 South America Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 83 South America Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2021-2030) ($MN)
  • Table 84 South America Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2021-2030) ($MN)
  • Table 85 South America Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 86 South America Influenza Diagnostic Tests Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 87 South America Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 88 South America Influenza Diagnostic Tests Market Outlook, By Serological Assay (2021-2030) ($MN)
  • Table 89 South America Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 90 South America Influenza Diagnostic Tests Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 91 South America Influenza Diagnostic Tests Market Outlook, By End User (2021-2030) ($MN)
  • Table 92 South America Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 93 South America Influenza Diagnostic Tests Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 94 South America Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2021-2030) ($MN)
  • Table 95 South America Influenza Diagnostic Tests Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 96 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 98 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 99 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2021-2030) ($MN)
  • Table 100 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By RT-PCR (2021-2030) ($MN)
  • Table 101 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 102 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2021-2030) ($MN)
  • Table 103 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2021-2030) ($MN)
  • Table 104 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 105 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 106 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 107 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Serological Assay (2021-2030) ($MN)
  • Table 108 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 109 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 110 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By End User (2021-2030) ($MN)
  • Table 111 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 112 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 113 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2021-2030) ($MN)
  • Table 114 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Other End Users (2021-2030) ($MN)